✦ LIBER ✦

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

✍ Scribed by O. L. Chinot; T. de La Motte Rouge; N. Moore; A. Zeaiter; A. Das; H. Phillips; Z. Modrusan; T. Cloughesy

Book ID: 107648738
Publisher: Springer Healthcare Communications
Year: 2011
Tongue: English
Weight: 625 KB
Volume: 28
Category: Article
ISSN: 0741-238X
DOI: 10.1007/s12325-011-0007-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and biomarker findings from AVa

Efficacy and biomarker findings from AVaglio, a phase III trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma

✍ Wick, W.; Cloughesy, T.; Mason, W.; Henriksson, R.; Saran, F.; Nishikawa, R.; Hi 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Phase II trial of temozolomide (TMZ) plu

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

✍ Jennifer A. Quinn; Sara Xiaoyin Jiang; David A. Reardon; Annick Desjardins; Jame 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 227 KB

Phase I Trial of Hypofractionated Intens

Phase I Trial of Hypofractionated Intensity-Modulated Radiotherapy With Temozolomide Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme

✍ Changhu Chen; Denise Damek; Laurie E. Gaspar; Allen Waziri; Kevin Lillehei; B.K. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 429 KB

Phase II study of temozolomide without r

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population

✍ Carol Alliot 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 1 views

Phase II study of temozolomide without r

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

✍ Olivier-L. Chinot; Maryline Barrie; Elisabeth Frauger; Henry Dufour; Dominique F 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND Currently, the survival of patients age > 70 years with glioblastoma multiforme (GBM) ranges from 4 months to 6 months, although radiotherapy and/or chemotherapy may prolong survival in certain subgroups. Temozolomide is an oral chemotherapeutic agent with efficacy agains

Phase II Trial of Lomustine Plus Temozol

Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03

✍ Herrlinger, U. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 212 KB